ClinicalTrials.gg
RecruitingNCT07258849Updated Jun 23, 2026

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

A Phase 1 interventional study of LY4213663 and LY4213663 in Rheumatoid Arthritis (RA), sponsored by Eli Lilly and Company. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.

Planned enrollment
21st of 35
141 · median 164
Started
2025
with 1 other
Phase 1
8 of 35
2 open now
Registered
34th of 35
by date

Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 21st largest by planned enrollment, is one of 2 that started in 2025, is one of 8 in phase 1, and was the 34th registered.

Arthritis, Rheumatoid

3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m²), inclusive

Part C and D Only:

  • Have a body weight at least 50 kilograms and BMI within the range 18.0 to 40.0 kg/m² (inclusive) at screening
  • Have a diagnosis of adult-onset RA for at least 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

Healthy Participants for SAD Part A and MAD Part B Only:

  • Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs

Participants with RA for Parts C and D Only:

  • Have Class 4 RA according to American College of Rheumatology (ACR) revised criteria
  • Have a 12-lead (ECG) abnormality at screening
  • Have a current or recent acute active infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (estimated)

Study arms

  • Experimental
    LY4213663 (Part A)

    Single-ascending dose (SAD) of LY4213663 administered subcutaneously (SC) and intravenously (IV) in healthy participants

    Drug: LY4213663

  • Placebo comparator
    Placebo (Part A)

    SAD placebo administered SC and IV

    Drug: Placebo

  • Experimental
    LY4213663 (Part B)

    Multiple-ascending doses (MAD) of LY4213663 administered SC and IV in healthy participants

    Drug: LY4213663

  • Placebo comparator
    Placebo (Part B)

    MAD placebo administered SC and IV

    Drug: Placebo

  • Experimental
    LY4213663 (Parts C and D)

    Multiple doses of LY4213663 administered SC and IV in participants with RA

    Drug: LY4213663

Interventions

  • DrugLY4213663

    Administered SC

  • DrugLY4213663

    Administered IV

  • DrugPlacebo

    Administered SC

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Week 33

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4213663

    PK: Cmax of LY4213663

    Time frame: Baseline up to Week 33

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY4213663

    PK: AUC of LY4213663

    Time frame: Baseline up to Week 33

07

Study locations

9 of 10 sites recruiting
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
    Recruiting
    • · Contact256-236-0055, ext 101
    • Vishala Chindalore · Principal investigator
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
    Recruiting
    • · Contact602-773-3020
    • Louise Taber · Principal investigator
  • Clinical Research of West Florida, Inc. (Clearwater)
    Clearwater, Florida 33765, United States
    Recruiting
    • · Contact727-466-0078
    • Robert Levin · Principal investigator
  • GNP Research at Mark Jaffe, MD
    Cooper City, Florida 33024, United States
    Recruiting
    • · Contact754-248-3589
    • Mark Jaffe · Principal investigator
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
    Recruiting
    • · Contact866-429-3700
    • Sharrell Cooper · Principal investigator
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
    Recruiting
    • · Contact704-526-6864
    • WILSON CUEVA · Principal investigator
  • Advanced Pharma CR, LLC
    Miami, Florida 33417, United States
    Recruiting
    • · Contact305-220-2727, Ext 802
    • Simon Abelson · Principal investigator
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
    Recruiting
    • · Contact305-330-9977
    • Christopher Mesa · Principal investigator
  • Oasis Clinical Research
    Las Vegas, Nevada 89121, United States
    Recruiting
    • · Contact702-832-1369
    • Stephen Tam · Principal investigator
  • Universitätsklinikum Charité
    Berlin, 10117, Germany
    Not yet recruiting
    • · Contact+49 30 450 539 200
    • Stanislav Ignatenko · Principal investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2028, 27 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 27 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 2, 2025
StartActual
Dec 2, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07258849
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Dec 2, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion